|
Schizophrenia
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our family-based association study also revealed a small but significant contribution of the IL3RA variants to susceptibility to schizophrenia in a Chinese population.
|
19281803 |
2009 |
|
Schizophrenia
|
0.330 |
Biomarker
|
disease |
PSYGENET |
In conclusion, our family-based association study also revealed a small but significant contribution of the IL3RA variants to susceptibility to schizophrenia in a Chinese population.
|
19281803 |
2009 |
|
Schizophrenia
|
0.330 |
Biomarker
|
disease |
PSYGENET |
Our results indicate a small but significant contribution of the IL3RA polymorphism to susceptibility to schizophrenia, suggesting that the IL3 pathway may be involved in schizophrenia.
|
18547720 |
2008 |
|
Schizophrenia
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate a small but significant contribution of the IL3RA polymorphism to susceptibility to schizophrenia, suggesting that the IL3 pathway may be involved in schizophrenia.
|
18547720 |
2008 |
|
Schizophrenia
|
0.330 |
GeneticVariation
|
disease |
LHGDN |
Our results indicate a small but significant contribution of the IL3RA polymorphism to susceptibility to schizophrenia, suggesting that the IL3 pathway may be involved in schizophrenia.
|
18547720 |
2008 |
|
Schizophrenia
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Sequencing of CSF2RA and its neighbor, IL3RA (interleukin 3 receptor alpha) in an independent case-control cohort revealed both common intronic haplotypes and several novel, rare missense variants associated with schizophrenia.
|
17522711 |
2007 |
|
Schizophrenia
|
0.330 |
GeneticVariation
|
disease |
LHGDN |
Sequencing of CSF2RA and its neighbor, IL3RA (interleukin 3 receptor alpha) in an independent case-control cohort revealed both common intronic haplotypes and several novel, rare missense variants associated with schizophrenia.
|
17522711 |
2007 |
|
Schizophrenia
|
0.330 |
Biomarker
|
disease |
PSYGENET |
Sequencing of CSF2RA and its neighbor, IL3RA (interleukin 3 receptor alpha) in an independent case-control cohort revealed both common intronic haplotypes and several novel, rare missense variants associated with schizophrenia.
|
17522711 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we describe the generation and characterization of a fully-human monoclonal antibody specific to CD123, a surface marker which is overexpressed in a variety of hematological disorders, including acute myeloid leukemia.
|
31326578 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these recent studies strongly support CD123 as an important therapeutic target for the treatment of BPDCN, while a possible in the treatment of AML and other hematological malignancies will have to be evaluated by in the ongoing clinical studies.
|
31547472 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD123 represents an important acute myeloid leukemia (AML) therapeutic target.
|
31323275 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
At the time of diagnosis, CD123 expression analysis using IHC may represent a clinically useful assessment for de novo AML patients.
|
30847774 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It has been reported that <i>FUS-ERG</i>-positive AML expresses CD123, a marker of LSC, in some cases.
|
31850234 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
CARs comprised of these D domains mediate potent T cell activation and cytolysis of CD123-expressing target cells and induce complete durable remission in two AML xenograft models.
|
31043341 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The addition of interferon (IFN)-γ and tumor necrosis factor (TNF)-α neutralizing antibodies can effectively reverse the upregulation of CD123 on the endothelial cells caused by CART123, while the cytotoxicity of CART123 in AML cell lines was not affected in vitro.
|
31417286 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
|
30291336 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical trials are underway investigating non-HLA matched T cells expressing anti-CD19 CARs for the treatment of B cell acute lymphoblastic leukemia (B-ALL) and anti-CD123 CAR for acute myeloid leukemia (AML).
|
30632623 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The interleukin-3 receptor α subunit, CD123, is expressed in many hematologic malignancies including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
|
31437130 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tagraxofusp (tagraxofusp-erzs) [Elzonris™] is an intravenously administered CD123-directed cytotoxin (composed of human interleukin-3 and a truncated diphtheria toxin payload) that was developed by Stemline Therapeutics, Inc. for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
|
30859413 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The performance characteristics of the TCF4/CD123 stain were evaluated in 48 confirmed BPDCN cases.
|
31261288 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> CD123-targeted chimeric antigen receptor (CAR) T cell (CART123) for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm has exhibited potential in clinical trials.
|
31417286 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The interleukin-3 receptor α subunit, CD123, is expressed in many hematologic malignancies including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
|
31437130 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tagraxofusp is an intravenously administered CD123-directed cytotoxin consisting of the fusion of interleukin-3 with a truncated diphtheria toxin payload and was recently approved by the Food and Drug Administration for the treatment of adults and children aged 2 and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
|
31465247 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given the promising results in early clinical trials, it appears CD123 is the most viable target for BPDCN, and future studies should continue to exploit its expression on BPDCN cells.
|
30715612 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Future directions in therapy approaches for patients with BPDCN will include the development of other CD123-targeted agents, agents targeting beyond CD123 and investigation of rational combination approaches of CD123-directed therapy with other therapies.
|
31579499 |
2019 |